UNCY Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
Cost of Revenue
0
0
0
0
0
Gross Profit
Operating Expenses
8.4M
+16.8%
7.2M
-1.6%
7.3M
+5.4%
7.0M
-12.8%
8.0M
R&D
1.6M
-28.6%
2.3M
-24.1%
3.0M
+69.4%
1.8M
-19.4%
2.2M
SG&A
6.8M
+37.3%
5.0M
+13.6%
4.4M
-16.0%
5.2M
-10.4%
5.8M
Operating Income
-8437000
-16.8%
-7224000
+1.6%
-7342000
-5.4%
-6963000
+12.8%
-7989000
EBITDA
-8429000
-16.8%
-7214000
+1.6%
-7332000
-5.4%
-6957000
+12.8%
-7981000
Net Income
-12823000
+12.6%
-14668000
-144.0%
-6011000
+6.8%
-6447000
-1231.1%
570.0K
EPS (Basic)
$-0.54
+34.1%
$-0.82
-148.5%
$-0.33
+36.5%
$-0.52
-1400.0%
$0.04
EPS (Diluted)
$-0.54
+34.1%
$-0.82
-148.5%
$-0.33
+36.5%
$-0.52
-4.0%
$-0.50
Shares (Diluted)
23.9M
+50.5%
15.9M
-12.1%
18.1M
+46.8%
12.3M
-0.7%
12.4M
Unicycive Therapeutics (UNCY) — Financials